Nutra Pharma Receives Patent For Novel Antiviral Treatment Using Modified Cobra VenomNutra Pharma Corporation (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), Multiple Sclerosis (MS) and Pain, announced that it has received approval from the United States Patent and Trademark Office (USPTO) for its patent describing a method of treating and preventing infectious diseases, i...
Back To The Future For Flu Fighters, AustraliaResearchers from The Australian National University have breathed new life into an old protein drug target in a discovery that could open the door to a new range of drugs to combat influenza...
Health-Care Workers And Seasonal Influenza Immunization RatesCampaigns to increase seasonal influenza vaccination rates amongst health care workers in Canada that include a combination of interventions had the greatest effect on increasing vaccine coverage, according to a study published in CMAJ (Canadian Medical Association Journal)...
Vaccine Via Dissolvable Microneedle Skin Patch Shows PromiseScientists in the US who developed a skin patch that uses hundreds of microscopic dissolvable needles to deliver vaccine into the body have shown it works on animals, perhaps even better than the traditional injection method; they envisage that one day this approach could reduce the cost and administration of mass vaccination, for instance during flu epidemics, because ...
On Track For A Universal Flu VaccineA universal influenza vaccine - so-called because it could potentially provide protection from all flu strains for decades - may become a reality because of research led by scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health...
Examining Human Immune Response To Virus At The Atomic LevelA team of biochemists has identified the molecular mechanism by which an immune response is triggered by the invading viruses, according to recent research. The results could eventually lead to new therapies for many different kinds of viral infections, from the common cold to hepatitis and AIDS, according to Dr. Pingwei Li, Texas A&M University's department of biochemistry and biophysics...
Influenza Vaccine Collaboration Between A*STAR And Cytos BiotechnologySwitzerland's Cytos Biotechnology and Singapore's Agency for Science, Technology and Research (A*STAR) have jointly announced their first collaboration on a virus-like particle (VLP) vaccine. This partnership, which involves academic and clinical partners across Singapore, aims at research, development and commercialisation of a VLP vaccine to manage influenza infections...
Brand-Nu Laboratories Introduces Chlophedianol HydrochlorideBrand-Nu Laboratories, a leading US-based high purity chemical manufacturer and distributor, has introduced Chlophedianol Hydrochloride, also known as Clofedanol Hydrochloride JP, to its product portfolio of active pharmaceutical ingredients (APIs). Chlophedianol Hydrochloride has been recognized as a possible replacement for Dextromethorphan in cough and cold formulations...
![](\"http://www.igotyourindex.com/igyindex.gif?DOCUMENTNAME=&DOCUMENTLINK=&GOALNAME&=DOCUMENTVALUE&=GROUPNAME\")